Clinical trial
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.
NCT07290166 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 31, 2025
- Completion date
- April 30, 2028
- Enrollment
- 42 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer